Romanski Annette, Bug Gesine, Becker Sven, Kampfmann Manuela, Seifried Erhard, Hoelzer Dieter, Ottmann Oliver G, Tonn Torsten
Center for Internal Medicine, Department of Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany.
Exp Hematol. 2005 Mar;33(3):344-52. doi: 10.1016/j.exphem.2004.11.006.
Natural killer (NK) cell-mediated cytotoxicity contributes to the innate immune response against numerous malignancies, including leukemias. Acute lymphoblastic leukemias (ALL) often display a high degree of resistance, the mechanisms of which have not been elucidated.
We used the well-characterized NK cell line NK-92 as a model to investigate whether mechanisms commonly implicated in tumor escape from NK cell killing are relevant for ALL.
We demonstrate selective resistance of B-precursor ALL to NK-92 cytotoxicity even in the absence of inhibitory killer cell immunoglobulin-like receptors (KIR), except for KIR2DL4. We also show that human leukocyte antigen-G, a ligand of KIR2DL4, expressed on a subset of ALL, does not mediate resistance of NK-cell mediated lysis. Similarly, intracellular adhesion molecule/lymphocyte function-associated antigen-1 interaction did not contribute significantly to resistance. In contrast the NK-sensitive T-ALL (MOLT-4) expressed moderate amounts of MHC class I chain-related gene AB (MICA/B) a ligand for the NK cell activating receptor NKG2D, while expression of MICA/B was absent in resistant B-ALL cell lines.
The NK cell-resistance of B-lineage ALLs does not appear to involve inhibitory mechanisms, but suggests deficient NK cell activation. Thus, immunostrategies designed to enhance ALL sensitivity toward NK cell-mediated cytotoxicity should focus on mechanisms of NK cell activation.
自然杀伤(NK)细胞介导的细胞毒性作用有助于机体对包括白血病在内的多种恶性肿瘤产生先天性免疫反应。急性淋巴细胞白血病(ALL)通常表现出高度耐药性,但其机制尚未阐明。
我们使用特征明确的NK细胞系NK-92作为模型,研究肿瘤逃避NK细胞杀伤的常见机制是否与ALL相关。
我们证明,即使在没有抑制性杀伤细胞免疫球蛋白样受体(KIR)(除KIR2DL4外)的情况下,B前体ALL对NK-92细胞毒性仍具有选择性抗性。我们还表明,在一部分ALL上表达的KIR2DL4配体人类白细胞抗原-G,并不介导NK细胞介导的裂解抗性。同样,细胞间黏附分子/淋巴细胞功能相关抗原-1相互作用对耐药性的贡献也不显著。相反,NK敏感的T-ALL(MOLT-4)表达适量的MHC I类链相关基因AB(MICA/B),它是NK细胞激活受体NKG2D的配体,而耐药的B-ALL细胞系中则不存在MICA/B的表达。
B系ALL的NK细胞抗性似乎不涉及抑制机制,而是提示NK细胞激活不足。因此,旨在增强ALL对NK细胞介导的细胞毒性敏感性的免疫策略应侧重于NK细胞激活机制。